MARKET INTRODUCTION
Vascular endothelial growth factor inhibitors are also called as angiogenesis inhibitors. They restrain the growth of new blood vessels. Angiogenesis inhibitors are useful in the treatment of cancer, macular degeneration in the eye, and diseases that involve the proliferation of blood vessels. VEGF is regulated by the activity of endogenous stimulators and inhibitors. Endogenous inhibitors are involved in the process of blood vessel formation. They are obtained from the cellular matrix and basement protein. Among the factors responsible for angiogenesis, VEGF is the most potent and has high expression in endometrial, ovarian, and cervical cancer. Inhibition of angiogenesis by VEGF needs anti-VEGF/ anti-angiogenesis factors, which decrease the production of pro-angiogenic factors, thereby restricting them from binding to their receptors. The commonly used therapy for VEGF pathway inhibition is a monoclonal antibody against soluble VEGFR hybrids, VEGF or VEGFR, and tyrosine kinase inhibitors. Monoclonal antibody Bevacizumab is widely used for treatment.
MARKET DYNAMICS
The increase in the prevalence of cancer and recognition of therapeutic opportunities and increasing investments in research and development will spur the demand for VEGF/VEGFR inhibitor drugs market. Additionally, increasing focus on developing personalize medicines and diagnostics expected to boost the market growth to significant extent over the forecast period. One of the factors restraining VEGF inhibitors from becoming a silver bullet in the treatment of cancer is that angiogenesis is not the only factor causing tumors. Also, other restraints include the side effects caused by VEGF inhibitors such as bleeding and increased blood pressure in the forecasted period.
MARKET SCOPE
The "Global VEGF/VEGFR Inhibitor Drugs Market Analysis to 2028" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of VEGF/VEGFR inhibitor drugs market with detailed market segmentation by type, application, and geography. The global VEGF/VEGFR inhibitor drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading VEGF/VEGFR inhibitor drugs market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The global VEGF/VEGFR inhibitor drugs market is segmented on the type, and application. Based on type, the global VEGF/VEGFR inhibitor drugs market is segmented into with tyrosine kinase inhibitors, monoclonal antibodies, and others. Based on the application, the VEGF/VEGFR inhibitor drugs market is oncology, ophthalmology, and others.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global VEGF/VEGFR inhibitor drugs market based on various segments. It also provides market size and forecast estimates from year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The VEGF/VEGFR inhibitor drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting VEGF/VEGFR inhibitor drugs market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the VEGF/VEGFR inhibitor drugs market in these regions.
MARKET PLAYERS
The reports cover key developments in the VEGF/VEGFR inhibitor drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from VEGF/VEGFR inhibitor drugs market are anticipated to lucrative growth opportunities in the future with the rising demand for VEGF/VEGFR inhibitor drugs market in the global market. Below mentioned is the list of few companies engaged in the VEGF/VEGFR inhibitor drugs market.
The report also includes the profiles of key VEGF/VEGFR inhibitor drugs market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- - Pfizer
- Novartis AG
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- Bristol-Myers Squibb Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Bayer AG
- Eli Lilly & Company
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.